Entropy Neurodynamics Ltd

0.032

+0.0013.23%

Volume:1.37M

Turnover:43.46K

Market Cap:51.50M

PE:-8.21

High:0.032

Open:0.031

Low:0.031

Close:0.031

52wk High:0.046

52wk Low:0.027

Shares:1.61B

Float Shares:878.05M

Volume Ratio:0.30

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.004

EPS(LYR):-0.004

ROE:-92.06%

ROA:-45.59%

PB:8.64

PE(LYR):-8.21

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Entropy Neurodynamics Says Phase 2a Trial Results of Binge Eating Disorder Drug Candidate Show a Sustained Reduction in Episodes of 80%, Shares Jump 3%

MT Newswires Live

·

Jan 13

Entropy Neurodynamics Completes Dosing of First Patient in Binge Eating Disorder Trial

MT Newswires Live

·

Dec 16, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENP.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","market":"AU","secType":"STK","nameCN":"Entropy Neurodynamics Ltd","latestPrice":0.032,"timestamp":1770613920000,"preClose":0.031,"halted":0,"volume":1371978,"delay":0,"changeRate":0.03225806451612906,"nameEN":"Entropy Neurodynamics Ltd","floatShares":878046607,"shares":1609510143,"eps":-0.0039,"marketStatus":"Not Yet Opened","change":0.001,"latestTime":"02-09 16:12:00 AEDT","open":0.031,"high":0.032,"low":0.031,"amount":43457,"amplitude":0.032258,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0039,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.031,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0.3024130701647713,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","floatShares":878046607,"roa":"-45.59%","roe":"-92.06%","lyrEps":-0.0039,"volumeRatio":0.3024130701647713,"shares":1609510143,"dividePrice":0,"high":0.032,"amplitude":0.032258,"preClose":0.031,"low":0.031,"week52Low":0.027,"pbRate":"8.64","psRate":"32.56","week52High":0.046,"institutionHeld":0,"latestPrice":0.032,"eps":-0.0039,"divideRate":0,"volume":1371978,"delay":0,"ttmEps":-0.0039,"open":0.031,"prevYearClose":0.033,"prevWeekClose":0.031,"prevMonthClose":0.031,"prevQuarterClose":0.033,"fiveDayClose":0.03,"twentyDayClose":0.033,"sixtyDayClose":0.038},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENP.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603576059","title":"Entropy Neurodynamics Says Phase 2a Trial Results of Binge Eating Disorder Drug Candidate Show a Sustained Reduction in Episodes of 80%, Shares Jump 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576059","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576059?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:09","pubTimestamp":1768273754,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said the results from its phase 2a clinical trial of its TRP-8802 drug candidate, or oral psilocin, for the treatment of binge eating disorder showed a sustained reduction in binge-eating episodes of 80% across patients, according to a Tuesday Australian bourse filing.The results were maintained through the 14-week follow-up period, alongside improvements across secondary outcomes, including reductions in anxiety, depression, psychological inflexibility, and waist circumference. They were published in the peer-reviewed Journal of Eating Disorders.The study enrolled six patients and involved therapy sessions before a single dose of TRP-8802, followed by structured supportive therapy. Of the six patients enrolled, five were available for data evaluation. Four of five participants were classified as none-to-mild binge eating disorder by week 14, per the filing.Its shares jumped 3% in recent trading on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"gpt_icon":0},{"id":"2591674455","title":"Entropy Neurodynamics Completes Dosing of First Patient in Binge Eating Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591674455","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591674455?lang=en_us&edition=fundamental","pubTime":"2025-12-16 11:04","pubTimestamp":1765854284,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  completed dosing of the first patient with the second infusion of its TRP-8803 drug candidate, or intravenous-infused psilocin, in its binge eating disorder trial being conducted alongside Swinburne University, according to a Tuesday Australian bourse filing.The planned clinical trial, which aims to recruit a total of 12 patients suffering from binge eating disorder, in two six-person groups, the company said. Each group will be given two doses of TRP-8803 14 days apart, along with supportive psychotherapy.The patient will undergo supportive psychotherapy, ahead of post-treatment review in four weeks, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","ENP.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ENP.AU\",params:#limit:6,delay:true,,,undefined,":[]}}